180 related articles for article (PubMed ID: 11559369)
1. Processing of natural and recombinant CXCR3-targeting chemokines and implications for biological activity.
Hensbergen PJ; van der Raaij-Helmer EM; Dijkman R; van der Schors RC; Werner-Felmayer G; Boorsma DM; Scheper RJ; Willemze R; Tensen CP
Eur J Biochem; 2001 Sep; 268(18):4992-9. PubMed ID: 11559369
[TBL] [Abstract][Full Text] [Related]
2. Cross reactivity of three T cell attracting murine chemokines stimulating the CXC chemokine receptor CXCR3 and their induction in cultured cells and during allograft rejection.
Meyer M; Hensbergen PJ; van der Raaij-Helmer EM; Brandacher G; Margreiter R; Heufler C; Koch F; Narumi S; Werner ER; Colvin R; Luster AD; Tensen CP; Werner-Felmayer G
Eur J Immunol; 2001 Aug; 31(8):2521-7. PubMed ID: 11500837
[TBL] [Abstract][Full Text] [Related]
3. CXCR3 requires tyrosine sulfation for ligand binding and a second extracellular loop arginine residue for ligand-induced chemotaxis.
Colvin RA; Campanella GS; Manice LA; Luster AD
Mol Cell Biol; 2006 Aug; 26(15):5838-49. PubMed ID: 16847335
[TBL] [Abstract][Full Text] [Related]
4. Human IP-9: A keratinocyte-derived high affinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3).
Tensen CP; Flier J; Van Der Raaij-Helmer EM; Sampat-Sardjoepersad S; Van Der Schors RC; Leurs R; Scheper RJ; Boorsma DM; Willemze R
J Invest Dermatol; 1999 May; 112(5):716-22. PubMed ID: 10233762
[TBL] [Abstract][Full Text] [Related]
5. Furin is a chemokine-modifying enzyme: in vitro and in vivo processing of CXCL10 generates a C-terminally truncated chemokine retaining full activity.
Hensbergen PJ; Verzijl D; Balog CI; Dijkman R; van der Schors RC; van der Raaij-Helmer EM; van der Plas MJ; Leurs R; Deelder AM; Smit MJ; Tensen CP
J Biol Chem; 2004 Apr; 279(14):13402-11. PubMed ID: 14739277
[TBL] [Abstract][Full Text] [Related]
6. Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function.
Colvin RA; Campanella GS; Sun J; Luster AD
J Biol Chem; 2004 Jul; 279(29):30219-27. PubMed ID: 15150261
[TBL] [Abstract][Full Text] [Related]
7. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties.
Proost P; Schutyser E; Menten P; Struyf S; Wuyts A; Opdenakker G; Detheux M; Parmentier M; Durinx C; Lambeir AM; Neyts J; Liekens S; Maudgal PC; Billiau A; Van Damme J
Blood; 2001 Dec; 98(13):3554-61. PubMed ID: 11739156
[TBL] [Abstract][Full Text] [Related]
8. The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis.
Hensbergen PJ; Wijnands PG; Schreurs MW; Scheper RJ; Willemze R; Tensen CP
J Immunother; 2005; 28(4):343-51. PubMed ID: 16000952
[TBL] [Abstract][Full Text] [Related]
9. Structure-function relationship between the human chemokine receptor CXCR3 and its ligands.
Clark-Lewis I; Mattioli I; Gong JH; Loetscher P
J Biol Chem; 2003 Jan; 278(1):289-95. PubMed ID: 12417585
[TBL] [Abstract][Full Text] [Related]
10. CCR3 functional responses are regulated by both CXCR3 and its ligands CXCL9, CXCL10 and CXCL11.
Xanthou G; Duchesnes CE; Williams TJ; Pease JE
Eur J Immunol; 2003 Aug; 33(8):2241-50. PubMed ID: 12884299
[TBL] [Abstract][Full Text] [Related]
11. Dipeptidyl peptidase IV (CD26) on T cells cleaves the CXC chemokine CXCL11 (I-TAC) and abolishes the stimulating but not the desensitizing potential of the chemokine.
Ludwig A; Schiemann F; Mentlein R; Lindner B; Brandt E
J Leukoc Biol; 2002 Jul; 72(1):183-91. PubMed ID: 12101279
[TBL] [Abstract][Full Text] [Related]
12. CXCR3 internalization following T cell-endothelial cell contact: preferential role of IFN-inducible T cell alpha chemoattractant (CXCL11).
Sauty A; Colvin RA; Wagner L; Rochat S; Spertini F; Luster AD
J Immunol; 2001 Dec; 167(12):7084-93. PubMed ID: 11739530
[TBL] [Abstract][Full Text] [Related]
13. Binding and functional properties of recombinant and endogenous CXCR3 chemokine receptors.
Weng Y; Siciliano SJ; Waldburger KE; Sirotina-Meisher A; Staruch MJ; Daugherty BL; Gould SL; Springer MS; DeMartino JA
J Biol Chem; 1998 Jul; 273(29):18288-91. PubMed ID: 9660793
[TBL] [Abstract][Full Text] [Related]
14. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.
Lasagni L; Francalanci M; Annunziato F; Lazzeri E; Giannini S; Cosmi L; Sagrinati C; Mazzinghi B; Orlando C; Maggi E; Marra F; Romagnani S; Serio M; Romagnani P
J Exp Med; 2003 Jun; 197(11):1537-49. PubMed ID: 12782716
[TBL] [Abstract][Full Text] [Related]
15. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3.
Cole KE; Strick CA; Paradis TJ; Ogborne KT; Loetscher M; Gladue RP; Lin W; Boyd JG; Moser B; Wood DE; Sahagan BG; Neote K
J Exp Med; 1998 Jun; 187(12):2009-21. PubMed ID: 9625760
[TBL] [Abstract][Full Text] [Related]
16. IL-4 enhances keratinocyte expression of CXCR3 agonistic chemokines.
Albanesi C; Scarponi C; Sebastiani S; Cavani A; Federici M; De Pità O; Puddu P; Girolomoni G
J Immunol; 2000 Aug; 165(3):1395-402. PubMed ID: 10903743
[TBL] [Abstract][Full Text] [Related]
17. Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration.
Proost P; Mortier A; Loos T; Vandercappellen J; Gouwy M; Ronsse I; Schutyser E; Put W; Parmentier M; Struyf S; Van Damme J
Blood; 2007 Jul; 110(1):37-44. PubMed ID: 17363734
[TBL] [Abstract][Full Text] [Related]
18. Expression of rat I-TAC/CXCL11/SCYA11 during central nervous system inflammation: comparison with other CXCR3 ligands.
McColl SR; Mahalingam S; Staykova M; Tylaska LA; Fisher KE; Strick CA; Gladue RP; Neote KS; Willenborg DO
Lab Invest; 2004 Nov; 84(11):1418-29. PubMed ID: 15322564
[TBL] [Abstract][Full Text] [Related]
19. A functional IFN-gamma-inducible protein-10/CXCL10-specific receptor expressed by epithelial and endothelial cells that is neither CXCR3 nor glycosaminoglycan.
Soejima K; Rollins BJ
J Immunol; 2001 Dec; 167(11):6576-82. PubMed ID: 11714827
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist.
Heise CE; Pahuja A; Hudson SC; Mistry MS; Putnam AL; Gross MM; Gottlieb PA; Wade WS; Kiankarimi M; Schwarz D; Crowe P; Zlotnik A; Alleva DG
J Pharmacol Exp Ther; 2005 Jun; 313(3):1263-71. PubMed ID: 15761110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
